Effect of icotinib plus gemcitabine and cisplatin chemotherapy on angiogenesis and treatment benefits in patients with advanced non-small cell lung cancer
OBJECTIVE To explore the effects of combining Icotinib with gemcitabine and cisplatin chemotherapy on angio-genesis and treatment outcomes in patients with advanced non-small cell lung cancer(NSCLC).METHODS Between January 2018 and December 2020,a total of 86 NSCLC patients were recruited and assigned into two groups of observation(n=43)and control(n=43).Control group received gemcitabine and cisplatin chemotherapy for 12 weeks while observation group had addi-tional icotinib dosing for 12 weeks.Comparison was conducted between two groups with regards to clinical efficacy,treatment-related toxic events,serum levels of angiogenic factors[vascular endothelial growth factor(VEGF),transforming growth factor-beta 1(TGF-β1),matrix metalloproteinase-9(MMP-9),tumor markers(cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen 125(CA125)& carcinoembryonic antigen(CEA)],as well as survival rates during 2-year follow-ups.RESULTS The overall response rate was significantly higher in observation group than that in control group(74.42％vs.34.88％)(P＜0.01).Additionally,observation group exhibited lower serum levels of VEGF,TGF-β1,MMP-9,CYFRA21-1,CA125 and CEA at Week 4/12 than those of control group(P＜0.05).The incidence of abnormal hepatorenal function,leuko-penia and thrombocytopenia was also lower in observation group than control group(P＜0.05).Furthermore,observation group demonstrated higher survival rates at Year 1/2 than control group(P＜0.05).CONCLUSION The combination therapy of ico-tinib with gemcitabine and cisplatin demonstrates remarkable efficacy and excellent safety for NSCLC.Furthermore,it exerts inhibitory effects on angiogenesis,enhances treatment efficacy and prolongs overall survival.
NETL
NSTL
万方数据
